TP53 and cancer: Additionally, our DisGeNET pathway analysis indicated that these genes are mainly enriched in mitotic G1 G1/S phase, signal transduction diseases, S phase, G1/S transition, interleukin-4 and 13 signaling, PI3K/AKT signaling in cancer, TP53-regulated cell cycle gene transcription, G1 phase, E2F1 target gene activation in G1/S phase, and E2F target gene transcription under DREAM complex negative control.